ES2560456T3 - Tratamiento de la tromboangeítis obliterante mediante la eliminación de autoanticuerpos - Google Patents
Tratamiento de la tromboangeítis obliterante mediante la eliminación de autoanticuerpos Download PDFInfo
- Publication number
- ES2560456T3 ES2560456T3 ES09753599.1T ES09753599T ES2560456T3 ES 2560456 T3 ES2560456 T3 ES 2560456T3 ES 09753599 T ES09753599 T ES 09753599T ES 2560456 T3 ES2560456 T3 ES 2560456T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- ligand
- plasma
- immunoglobulin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 206010043540 Thromboangiitis obliterans Diseases 0.000 title abstract description 5
- 208000033386 Buerger disease Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 claims abstract description 48
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 47
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 230000008030 elimination Effects 0.000 description 12
- 238000003379 elimination reaction Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 238000002266 amputation Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- -1 IgD Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101100257994 Arabidopsis thaliana FAB2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 208000037908 antibody-mediated disorder Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000006515 benzyloxy alkyl group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000013186 photoplethysmography Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08075309A EP2110140A1 (en) | 2008-04-18 | 2008-04-18 | Treatment of thromboangiitis obliterans by removal of autoantibodies |
| EP08075309 | 2008-04-18 | ||
| PCT/EP2009/002993 WO2009143944A2 (en) | 2008-04-18 | 2009-04-20 | Treatment of thromboangiitis obliterans by removal of autoantibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2560456T3 true ES2560456T3 (es) | 2016-02-19 |
Family
ID=39683905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09753599.1T Active ES2560456T3 (es) | 2008-04-18 | 2009-04-20 | Tratamiento de la tromboangeítis obliterante mediante la eliminación de autoanticuerpos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8663147B2 (enExample) |
| EP (2) | EP2110140A1 (enExample) |
| JP (1) | JP5718807B2 (enExample) |
| CN (1) | CN102006888A (enExample) |
| CA (1) | CA2721061C (enExample) |
| ES (1) | ES2560456T3 (enExample) |
| WO (1) | WO2009143944A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11008365B2 (en) | 2016-09-01 | 2021-05-18 | National Institute Of Advanced Industrial Science And Technology | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1409245A1 (ru) | 1985-04-12 | 1988-07-15 | Научно-исследовательский институт травматологии и ортопедии | Способ лечени врожденного вывиха бедра |
| SU1409275A1 (ru) * | 1985-06-10 | 1988-07-15 | Томский Медицинский Институт | Способ лечени псориаза |
| ATE266415T1 (de) * | 1995-11-15 | 2004-05-15 | Edwards Lifesciences Corp | Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern |
| RU2153168C2 (ru) | 1997-11-25 | 2000-07-20 | Научно-исследовательский институт кардиологии | Способ определения показаний к проведению плазмафереза при лечении стенокардии |
| US6551266B1 (en) | 1998-12-29 | 2003-04-22 | Occulogix Corporation | Rheological treatment methods and related apheresis systems |
| EP2228389B1 (en) * | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
| DE102006003782A1 (de) | 2006-01-25 | 2007-08-02 | Protagen Ag | Immunadsorptionstherapie mittels Autoantigenen |
| US20100047211A1 (en) * | 2006-05-19 | 2010-02-25 | The Johns Hopkins University | Method of growth of mesenchymal cells under non-adherent conditions for clinical applications |
| US8088600B2 (en) * | 2006-10-18 | 2012-01-03 | Centocor Ortho Biotech Inc. | Nucleic acids encoding cynomolgus IL-13 mutein proteins |
| WO2008151847A1 (en) | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Autoantibody binding peptides and their use for the treatment of vascular diseases |
-
2008
- 2008-04-18 EP EP08075309A patent/EP2110140A1/en not_active Withdrawn
-
2009
- 2009-04-20 JP JP2011504387A patent/JP5718807B2/ja not_active Expired - Fee Related
- 2009-04-20 CA CA2721061A patent/CA2721061C/en not_active Expired - Fee Related
- 2009-04-20 EP EP09753599.1A patent/EP2288384B1/en not_active Not-in-force
- 2009-04-20 US US12/988,267 patent/US8663147B2/en not_active Expired - Fee Related
- 2009-04-20 CN CN2009801134903A patent/CN102006888A/zh active Pending
- 2009-04-20 ES ES09753599.1T patent/ES2560456T3/es active Active
- 2009-04-20 WO PCT/EP2009/002993 patent/WO2009143944A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011517690A (ja) | 2011-06-16 |
| US8663147B2 (en) | 2014-03-04 |
| CN102006888A (zh) | 2011-04-06 |
| WO2009143944A2 (en) | 2009-12-03 |
| CA2721061C (en) | 2016-06-28 |
| EP2288384A2 (en) | 2011-03-02 |
| EP2110140A1 (en) | 2009-10-21 |
| JP5718807B2 (ja) | 2015-05-13 |
| CA2721061A1 (en) | 2009-12-03 |
| WO2009143944A3 (en) | 2010-08-05 |
| US20110105980A1 (en) | 2011-05-05 |
| EP2288384B1 (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2414872T3 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
| Chaung et al. | Mitochondrial transcription factor A is a proinflammatory mediator in hemorrhagic shock | |
| CN1160126C (zh) | 败血症治疗用免疫吸附剂 | |
| Mitzner et al. | Extracorporeal endotoxin removal by immobilized polyethylenimine | |
| ES2547547T3 (es) | Enriquecimiento de lipoproteínas de alta densidad pre-beta | |
| JP2008506665A5 (enExample) | ||
| JP2002504831A (ja) | 自己抗体の除去による心筋症の処置 | |
| ES2298789T3 (es) | Dispositivo de aferesis. | |
| RU2011150495A (ru) | Способы и композиции для лечения волчанки | |
| Terman et al. | Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single vs combination chemotherapeutic agents | |
| Linden et al. | Extracorporeal blood purification in burns: a review | |
| JP2012526846A5 (enExample) | ||
| ES2560456T3 (es) | Tratamiento de la tromboangeítis obliterante mediante la eliminación de autoanticuerpos | |
| ES2664350T3 (es) | Uso de una solución de citrato para la eliminación cromatográfica de afinidad de proteína C-reactiva (PCR) mediante fosfocolina y sus derivados | |
| Yamamoto et al. | Plasma adiponectin levels in acute liver failure patients treated with plasma filtration with dialysis and plasma exchange | |
| JP2012520306A (ja) | 免疫調節治療剤 | |
| Kasuya et al. | Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus | |
| ES2423007T3 (es) | Uso de una matriz para la eliminación de proteína C reactiva de fluidos biológicos | |
| Blaha et al. | Experience with extracorporeal elimination therapy in myasthenia gravis | |
| ES2433280T3 (es) | Adsorbente inmunológico para el tratamiento de inflamaciones | |
| Ptak et al. | Immunoadsorption therapy and complement activation | |
| Roth et al. | Pro-inflammatory interleukin-18 and caspase-1 serum levels in liver failure are unaffected by MARS treatment | |
| Munk et al. | Goodpasture's syndrome--effects of plasmapheresis | |
| Mistry et al. | The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome | |
| RU2052998C1 (ru) | Способ лечения иммунокомплексных состояний |